eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.: joe khamisi book ‘looters and grabbers’ not sold in kenyan stores
.
.
. the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe.
.
.
. severe psoriasis. credit: penn medicine
.